DocWire News Editors

DocwireNews

Histological and cytomorphological examinations are vital to diagnosis of myelodysplastic syndromes (MDS). But accurate diagnosis can still be challenging and variable, especially in patients with pancytopenia or in cases when the diagnostician has limited experience.In an effort to improve diagnostic accuracy, a group of researchers has developed and validated a model that uses mutational data, peripheral blood counts, and clinical variables to differentiate MDS from other myeloid malignancies. They presented their work at the 62nd ASH Annual Meeting &amp; Exposition.The team collected data on 652 patients treated at Cleveland Clinic in Ohio, 1,509 patients from at Munich Leukemia Laboratory in Germany, and 536 patients from the University of Pavia in Italy.All of the patients had been diagnosed with one of the following based on bone marrow aspiration according to World Health Organization 2017 criteria:<ul>
<li>MDS</li>
<li>Chronic myelomonocytic leukemia (CMML)</li>
<li>MDS/myeloproliferative neoplasm (MPN) overlap (MDS-MPN)</li>
<li>MPN</li>
<li>Clonal cytopenia of undetermined significance (CCUS)</li>
<li>Idiopathic cytopenia of undetermined significance (ICUS)</li>
</ul>The study collected clinical and genomic data, including commercially available next-generation sequencing panels. Clinical characteristics included:<ul>
<li>Median age was 70 years</li>
<li>Median hemoglobin was 10.4g/dL</li>
<li>Median platelet count was 132 k/dL</li>
<li>Median white blood cell count was 5.3 k/dL</li>
<li>Median absolute neutrophil count was 2.8 k/dL</li>
<li>Median monocyte count was 0.3 k/dL</li>
<li>Median lymphocyte count was 1.1 k/dL</li>
<li>Median peripheral blast percentage was 0%</li>
</ul>Then, the team used a machine learning algorithm to build a model based on the genomic and clinical variables. They trained and tested the model on the Cleveland Clinic and University of Pavia patients, then independently validated the final model with the Munich cohort.They found that the most commonly mutated genes in all patients and in the patients with MDS were&nbsp;SF3B1&nbsp;(27%),&nbsp;TET2&nbsp;(25%),&nbsp;ASXL1&nbsp;(19%),&nbsp;SRSF2&nbsp;(16%), and&nbsp;DNMT3A&nbsp;(11%). In CMML and MDS-MPN, the most commonly mutated genes were TET2 (46%), ASXL1 (34%), SRSF2 (29%), RUNX1 (13%), and CBL (12%). In patients with MPN, the study identified JAK2 (64%), ASXL1 (27%), TET2 (14%), DNMT3A (8%), and U2AF1 (7%). Finally, among patients with CCUS, the most commonly mutated genes were TET2 (41%), DNMT3A (27%), ASXL1 (19%), (SRSF2 17%), and ZRSR2 (10%). The results on ICUS were not reported.The most important features for model predictions, in order of importance, were:<ul>
<li>Number of mutations detected</li>
<li>Peripheral blast percentage</li>
<li>Absolute monocyte&nbsp;count</li>
<li>JAK2status</li>
<li>Hemoglobin</li>
<li>Basophil count</li>
<li>Age</li>
<li>Eosinophil count</li>
<li>Absolute lymphocyte count</li>
<li>White blood cell count</li>
<li>EZH2mutation status</li>
<li>Absolute neutrophil count</li>
<li>Mutation status of&nbsp;KRAS&nbsp;and&nbsp;SF3B1</li>
<li>Platelets</li>
<li>Gender</li>
</ul>&ldquo;The model can provide personalized interpretations of its outcome and can aid physicians and hematopathologists in recognizing MDS with high accuracy when encountering patients with pancytopenia and with a suspected diagnosis of MDS,&rdquo; said lead presenter Nathan Radakovich, BA, of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Ohio. &ldquo;The model also provides individual-level explanations for predictions, providing top differential diagnoses and individual-level explanations of how features influence a putative diagnosis.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

A Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

ASH Annual Meeting 2020

Histological and cytomorphological examinations are vital to diagnosis of myelodysplastic syndromes (MDS). But accurate diagnosis can still be challenging and variable, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe